These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27623022)

  • 41. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
    D'Angelo D; Borbone E; Palmieri D; Uboldi S; Esposito F; Frapolli R; Pacelli R; D'Incalci M; Fusco A
    Eur J Cancer; 2013 Mar; 49(5):1142-51. PubMed ID: 23149213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.
    Le VH; Inai M; Williams RM; Kan T
    Nat Prod Rep; 2015 Feb; 32(2):328-47. PubMed ID: 25273374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acylhydrazone derivatives: a patent review.
    Maia Rdo C; Tesch R; Fraga CA
    Expert Opin Ther Pat; 2014 Nov; 24(11):1161-70. PubMed ID: 25213630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
    Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
    Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trabectedin has promising antineoplastic activity in high-grade meningioma.
    Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
    Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.
    Cioffi A; Italiano A
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):113-22. PubMed ID: 22176591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
    Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
    Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M; Jimeno J
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.
    Liu SV; Zneimer S; Tahbaz A; Douer D
    Acta Haematol; 2011; 126(2):76-8. PubMed ID: 21502754
    [No Abstract]   [Full Text] [Related]  

  • 50. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
    Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The intriguing patterns of tumor response to trabectedin.
    Sanfilippo R; Casali PG
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Berberine and its derivatives: a patent review (2009 - 2012).
    Singh IP; Mahajan S
    Expert Opin Ther Pat; 2013 Feb; 23(2):215-31. PubMed ID: 23231038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).
    Marzaro G; Guiotto A; Chilin A
    Expert Opin Ther Pat; 2012 Mar; 22(3):223-52. PubMed ID: 22404097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent development on naphthoquinone derivatives and their therapeutic applications as anticancer agents.
    Tandon VK; Kumar S
    Expert Opin Ther Pat; 2013 Sep; 23(9):1087-108. PubMed ID: 23651032
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.
    Ferrandina G; Salutari V; Vincenzi B; Marinaccio M; Naglieri E; Loizzi V; Carpano S; Amadio G; Tonini G; Scambia G; Lorusso D
    Gynecol Oncol; 2013 Sep; 130(3):505-10. PubMed ID: 23774301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.
    Vincenzi B; Stumbo L; Maltese G; Cerbone L; Spalato Ceruso M; Badalamenti G; Santini D; Tonini G; Frezza AM; De Lisi D; Silletta M
    Sci Rep; 2015 Aug; 5():12077. PubMed ID: 26235506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can hepatocellular carcinoma be treated by Yondelis through targeting both tumor cells and tumor-associated macrophages?
    Zhang CH; Xu GL; Jia WD; Ge YS; Wang W
    Hepatogastroenterology; 2010; 57(97):114-6. PubMed ID: 20422884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.
    Pick AM; Nystrom KK
    J Oncol Pharm Pract; 2010 Dec; 16(4):269-72. PubMed ID: 20015930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.
    Achary R; Yun JI; Park CM; Mathi GR; Lee JY; Ha JD; Chae CH; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P
    Bioorg Med Chem; 2016 Jan; 24(2):207-19. PubMed ID: 26712094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Going further in the knowledge of Yondelis®; what's new in clinical trials?
    Blay JY
    Future Oncol; 2014 Jun; 10(8 Suppl):s7-s12. PubMed ID: 25048046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.